Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00166426
NCT00166426
Completed
Phase 2

Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy

Mayo Clinic1 site in 1 country240 target enrollmentFebruary 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstatic Neoplasms
DrugsExisulind

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Prostatic Neoplasms
Sponsor
Mayo Clinic
Enrollment
240
Locations
1
Primary Endpoint
Assess efficacy of drug vs placebo regarding cancer specific survival
Status
Completed
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.

Registry
clinicaltrials.gov
Start Date
February 2003
End Date
May 2008
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Assess efficacy of drug vs placebo regarding cancer specific survival

Assess efficacy of drug vs placebo regarding overall rate of biochemical progression

Assess the efficacy of drug vs placebo regarding time to biochemical progression

Assess efficacy of drug vs placebo regarding overall rate of clinical progression

Assess efficacy of drug vs placebo regarding time to clinical progression

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 4
A Study of Tadalafil After Radical ProstatectomyErectile Dysfunction
NCT01026818Eli Lilly and Company583
Completed
Phase 3
Study of Immunotherapy to Treat Advanced Prostate CancerProstate Cancer
NCT00861614Bristol-Myers Squibb988
Recruiting
N/A
Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)Prostate Cancer Metastatic
NCT03129854Sun Yat-sen University250
Completed
Phase 2
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer PatientsProstate Cancer
NCT00466440Eli Lilly and Company108
Completed
Phase 1
Advanced Pelvic Floor Training Program for Prostate Cancer SurgeryProstate Cancer Patients Undergoing Radical Prostatectomy
NCT02233608University of Guelph-Humber88